New understanding and research progression for triplenegative breast cancer

doi:10.3760/cma.j.issn.1673-422X.2013.11.014

Abstract

Abstract: Triplenegative breast cancer (TNBC) is a heterogeneous disease. It has distinct risk factors, molecular biology features, clinical presentations and prognosis. TNBC recurrence is common after resection, and the survival rate is low and available treatment options are few after recurrence. To date, chemotherapy is the main treatment strategy for TNBC. There is a great need for new molecular predictive marks and drug targets for improving the efficacy of TNBC treatment.

Key words: Breast neoplasms, Drug therapy, Triple negative

WANG Xin-Zhao, ZUO Wen-Shu, YU Zhi-Yong. New understanding and research progression for triplenegative breast cancer[J]. Journal of International Oncology, 2013, 40(11): 846-849.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics.CA Cancer J Clin，2011,61(2):69-90. ［2］ Cheang MC, Voduc D, Bajdik C, et al. Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 2008, 14(5):1368-1376. ［3］ Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist, 2010, 15(Suppl 5):39-48. ［4］ de Ronde JJ, Hannemann J, Halfwerk H, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat, 2010, 119(1):119-126. ［5］ Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat, 2009, 113(2):357-370. ［6］ Perez CA, Zumsteg ZS, Gupta G, et al. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast cancer research and treatment, 2013, 139(2):497-506. ［7］ Evans DG, Howell A. Are we ready for online tools in decision making for BRCA1/2 mutation carriers?. J Clin Oncol, 2012, 30(5):471-473. ［8］ Wang Y, Ikeda DM, Narasimhan B, et al. Estrogen receptor negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology, 2008, 246(2):367-375. ［9］ Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triplenegative breast cancer: clinicopathological characteristics and relationship with basallike breast cancer. Mod Pathol, 2010,23(1):123133. ［10］ Persson M, Andrén Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA, 2009,106(44):1874018744. ［11］ Jatoi I, Anderson WF, Jeong JH, et al. Breast cancer adjuvant therapy: time to consider its time-ependent effects. J Clin Oncol, 2011, 29(17):2301-2304. ［12］ Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat, 2012, 133(3):831-841. ［13］ Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res, 2012, 14(1):R3. ［14］ Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat, 2011, 127(3):713-720. ［15］ Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol, 2012, 29(2):526-533. ［16］ Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res, 2010, 12(5):R68. ［17］ von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant che-motherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 2012, 30(15):1796-1804. ［18］ Zumsteg ZS, Morrow M, Arnold B, et al. Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T_1-2N₀ Triple-Negative Breast Cancer. An Surg Oncol, 2013, 20(11):3469-3476. ［19］ Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triplenegative breast cancer. J Clin Oncol, 2012, 30(15):1879-1887. ［20］ Ignatov T, Poehlmann A, Ignatov A, et al. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. Breast Cancer Res Treat, 2013, 141(2):205-212. ［21］ Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triplenegative) breast cancer. Breast Cancer Res Treat, 2010, 121(2):261-271. ［22］ Erten C, Demir L, Somali I, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?. Asian Pac J Cancer Prev, 2013, 14(6):3711-3717. ［23］ Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2010, 28(20):3239-3247. ［24］ Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat, 2012, 133(3):1067-1075. ［25］ Yadav S, Sehrawat A, Eroglu Z, et al. Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PloS one, 2013, 8(5):e64338.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[6]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[9]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[10]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[11]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[12]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[13]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[14]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[15]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.